

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9508129/publications.pdf>

Version: 2024-02-01

19
papers

1,880
citations

759233

12
h-index

888059

17
g-index

19
all docs

19
docs citations

19
times ranked

3683
citing authors

#	ARTICLE	IF	CITATIONS
1	Biglycan as a potential regulator of tumorigenicity and immunogenicity in K-RAS-transformed cells. <i>OncolImmunology</i> , 2022, 11, 2069214.	4.6	4
2	Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma. <i>Cancers</i> , 2021, 13, 3907.	3.7	6
3	Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 371.	4.4	7
4	The Role of the RNA-Binding Protein Family MEX-3 in Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5209.	4.1	15
5	“Tumor immunology meets oncology (TIMO) XV”, April 25th–27th 2019, Halle/Saale, Germany. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 901-909.	4.2	0
6	What turns CREB on? And off? And why does it matter?. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 4049-4067.	5.4	92
7	CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6499.	3.3	21
8	Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. <i>Methods in Molecular Biology</i> , 2019, 1913, 13-31.	0.9	12
9	“Tumor Immunology Meets Oncology (TIMO) XIV”, May 24th–26th 2018, Halle/Saale, Germany. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1725-1732.	4.2	0
10	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. <i>Breast Care</i> , 2018, 13, 16-21.	1.4	135
11	Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells. <i>OncolImmunology</i> , 2018, 7, e1373233.	4.6	19
12	Linking CREB function with altered metabolism in murine fibroblast-based model cell lines. <i>Oncotarget</i> , 2017, 8, 97439-97463.	1.8	18
13	Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target. <i>Oncotarget</i> , 2016, 7, 35454-35465.	1.8	104
14	LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. <i>Cell Metabolism</i> , 2016, 24, 657-671.	16.2	1,126
15	Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization. <i>Oncotarget</i> , 2016, 7, 52061-52084.	1.8	11
16	Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Research</i> , 2015, 13, 1248-1262.	3.4	22
17	Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity. <i>Clinical Cancer Research</i> , 2014, 20, 4096-4106.	7.0	230
18	HER-2/neu Mediates Oncogenic Transformation via Altered CREB Expression and Function. <i>Molecular Cancer Research</i> , 2013, 11, 1462-1477.	3.4	30

#	ARTICLE	IF	CITATIONS
19	HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties. Journal of Biological Chemistry, 2012, 287, 24320-24329.	3.4	28